, a healthtech company started by 泭釵棗-款棗喝紳餃梗娶 , has a $100 million Series G round at a post-money valuation of $5 billion. The money comes less than 10 months after Tempus raised a $200 million at a pre-money valuation of $2.9 billion.
Subscribe to the 做厙勛圖 Daily
, , , and participated in the financing. With the latest round, Tempus has now raised $620 million since its September 2015 inception, according to 做厙勛圖 Previous backers include and Denmark���s .
Tempus says it has built an operating system to deliver personalized cancer care. It���s using its new capital to expand�� into other disease areas, including diabetes, depression and cardiology.
The startup is on a mission to redefine how genomic data is used in a clinical setting. It���s built out an interactive analytical and machine-learning platform so patients can benefit ���from the treatment of others who came before.���
Tempus��� genomics tests analyze DNA, RNA and proteomic data to understand a patient���s tumor at the molecular level with the goal of identifying customized treatment options.
Currently, Tempus works with thousands of oncologists across hundreds of medical systems. It claims to have the ���world���s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful.���
As anyone who���s had a family member battle cancer can attest to, the thought of more personalized (and better!) care is more than welcome.
Illustration:
Stay up to date with recent funding rounds, acquisitions, and more with the 做厙勛圖 Daily.


67.1K Followers